View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

CROSSJECT appoints Lionel Seltz as Chief Financial Officer

CROSSJECT appoints Lionel Seltz as Chief Financial Officer  DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto-injector platform, notably ZEPIZURE® for the emergency treatment of epileptic seizures, today announces the appointment of Lionel Seltz as Chief Financial Officer. Before joining CROSSJECT, Lionel Seltz served as CFO North Europe at Antech Diagnostics, where he led finance across several countries within a large interna...

 PRESS RELEASE

CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Fi...

CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, en phase avancée de développement et d'enregistrement de ZEPIZURE®, un injectable pour la prise en charge des crises d'épilepsie, annonce aujourd’hui la nomination de Lionel SELTZ en qualité de Directeur Administratif et Financier. Avant de rejoind...

Fabrice Farigoule
  • Fabrice Farigoule

FY25 results: no big change.

FY25 results: no big change. EARNINGS/SALES RELEASES The FY25 results were unsurprising, as the focus for Crossject remains on the future launch of Zeneo. The additional contribution from BARDA slightly reduces losses. However, cash consumption suggests the possibility of further dilution before achieving key operational milestones, such as the initial deliveries to BARDA. We do not anticipate significant changes to our valuation. FACT The group published its FY25 results. Operating income i...

Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
Kristof Samoy
  • Kristof Samoy

Vopak Catalysts ahead amid energy market turmoil - Valuation still att...

A global footprint and diversified terminal portfolio, supported by controlled leverage, lengthening contract durations and CPI indexed terms are the backbone of Vopak's defensive business model. Current energy market turmoil may temporarily affect performance but is also increasing storage demand amid energy security concerns and the shift toward a multi fuel energy system. FID announcements should act as catalysts, while cash returns offer downside protection. Buy reiterated and TP to €56 (fro...

 PRESS RELEASE

CROSSJECT publishes its 2025 financial results and confirms the streng...

CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration of ZEPIZURE®, an injectable for the management of epileptic seizures, today publishes its financial results for the financial year ended 31 December 2025...

 PRESS RELEASE

CROSSJECT publie ses résultats financiers 2025 et confirme le renforce...

CROSSJECT publie ses résultats financiers 2025 et confirme le renforcement de sa trajectoire opérationnelle, industrielle et financière  DIJON, France – 24 mars 2026 (18H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, en phase avancée de développement et d'enregistrement de ZEPIZURE®, un injectable pour la prise en charge des crises d'épilepsie, publie aujourd’hui ses résultats financiers pour l’exercice ...

Dirk Verbiesen ... (+7)
  • Dirk Verbiesen
  • Marc Hesselink
  • CFA
  • Marc Zwartsenburg
  • CEFA
  • Quirijn Mulder
  • Stijn Demeester

Middle East - Iran turmoil/Impact assessment

In this ING equities impact assessment of the situation in the Middle East report, we focus on a selection of 11 companies which we cover and we expect to be impacted by the current situation in the Middle East following the war in Iran, which started on 28 February and has since spread further into the region. We found that every company in this report faces its own challenges in the short term, while we also discuss the longer-term strategic implications.

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin
Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch